Hospitalisation insurance does not cover all the costs associated with cancer treatment, such as experimental therapies, non-medical expenses, or even lost income.
With the recent announcement on cancer treatment caps for Integrated Shield Plans (IPs), it’s even more imperative that you consider a dedicated cancer cover plan that provides an additional layer of protection.
In the past, many could rely on MediShield Life to cover a significant portion of hospital expenses, with only the co-insurance and deductible as out-of-pocket costs. However, MOH’s new regulations have shifted the landscape.
From April 1 2023, IPs will no longer offer ‘as charged’ cancer coverage6. Instead, they will only provide a maximum coverage of five times the amount offered by basic MediShield Life for cancer treatments. At the same time, only drugs that are on the Cancer Drug List (CDL) will be subsidised. For patients, especially those who require more complex and intensive treatments or experimental drugs, the reduced coverage can lead to hefty out-of-pocket expenses that may be hard to bear.
IPs riders can offer higher coverage but they can be costly. To avoid being blindsided, it’s important to review your cancer coverage. With the new IP changes, is there a protection gap and will your existing hospitalisation insurance be sufficient?
If not, consider getting a dedicated cancer insurance plan which not only makes sure that you can afford the treatment required, but also provides financial support for other non-medical costs such as loss of income, daily expenses, and caregiving among others.
With a cancer insurance plan like Etiqa Cancer Insurance, a lump sum is paid upon a cancer diagnosis – including the early stages – to ensure that you have the financial support required to focus on your treatment and recovery.